Sunday, February 28th | 16 Adar 5781

January 26, 2021 8:51 am

No Serious COVID-19 Cases Among Israelis Given Pfizer Shot, Minister Says

avatar by Reuters and Algemeiner Staff

A teenager receives a vaccination against the coronavirus disease (COVID-19), in Tel Aviv, Israel, January 24, 2021. REUTERS/Ronen Zvulun/File Photo

Israel, which has already given a full set of Pfizer/BioNTech vaccinations to over 6% of its citizens, has not registered a single serious COVID-19 case among them, even as infections surge in the wider population, the government said on Tuesday.

Health Minister Yuli Edelstein told a parliamentary panel that new infections and hospital admissions for serious or critical COVID-19 complications were now at record numbers.

But he said he knew of “no serious morbidity” among Israelis eligible for the vaccination certificate — a document issued by the state a week after the second dose is administered, when Pfizer says the vaccine is 95% effective. He said 0.014% had contracted milder forms of COVID-19.

Israel began what has become the world’s fastest per capita distribution of vaccines against the new coronavirus on Dec. 19, using the shot developed by the American firm Pfizer Inc. and Germany’s BioNTech.

Related coverage

February 28, 2021 12:50 pm

‘By 2025, 55% Of Our Products Will Be Made of Recycled Plastic,’ Says Israeli Plastics Company Keter’s Co-CEO

CTech - “We have given ourselves a short-term goal that by 2025 more than half of our raw materials will...

According to Health Ministry figures, 23% have received the first shot and more than 6% the second, between 21 and 28 days later.

The ministry blames highly communicable variants originating abroad for setbacks in Israel‘s bid to halt the spread of the virus.

A week after beginning vaccinations, it imposed its third national lockdown, which officials say may need to be extended into February.

But last Thursday it reported a reproduction number — known as “R” — of less than 1, which indicates that epidemic is no longer growing.

Share this Story: Share On Facebook Share On Twitter

Let your voice be heard!

Join the Algemeiner

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.